You’ve spent months working on the asset. The clinical strategy has been debated. The data have been reviewed from every angle. The
When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might think pharmaceutical companies are sitting
Intro Teams often fail not because of a lack of data, but because of research that confirms what they already believe. The
Two crucial questions I’ve tackled in numerous projects for new life science products designed for hospitals are: who are the decision-makers, and
Has the influence of finance in biopharma helped or hindered addressing unmet needs and getting treatments to patients? Roy Victor’s book is
Intro You, your internal strategy/research/insights team, and one or more vendors have just wrapped up a project to support a drug, medical
Getting up to speed quickly on a new disease area is something myself and many in Business Development, New Product Planning, Competitive
Intro This is part of a series of articles covering past projects to help existing and potential clients understand the journey of
This week I’m sharing a book recommendation rather than a blog post. I have slowly been working through the books available on
Intro For Pharma companies looking to differentiate and strengthen their drugs with a beyond-the-molecule offering, a clinical decision support system (CDSS or
Getting a Nature + subscription was one of the best decisions we made this year. For £15 a month we get access
It is all too easy to copy your competitor(s) after you have conducted a benchmarking project. But take a pause before starting
Intro This is the second article discussing how to run a benchmarking project. If you haven’t read the first, in which we
Intro As I continue the series of articles on the projects we specialize in at SiVan Consulting, I thought I would tackle
This post is part of a series of articles I plan to write for past projects to help existing and potential clients
